Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NETWORK 4NIH 3OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 205Carcinoma, Non-Small-Cell Lung 130Neoplasms 101Neoplasm Metastasis 70Breast Neoplasms 66Ovarian Neoplasms 42Urinary Bladder Neoplasms 37Lung Neoplasms 37Triple Negative Breast Neoplasms 34Colorectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Cholangiocarcinoma 28Biliary Tract Neoplasms 27Carcinoma, Transitional Cell 23Lymphoma, Non-Hodgkin 22Adenocarcinoma 22Recurrence 21Lymphoma 20Fallopian Tube Neoplasms 18Stomach Neoplasms 15Sarcoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 15Non-Muscle Invasive Bladder Neoplasms 13Carcinoma, Pancreatic Ductal 13Nasopharyngeal Carcinoma 12Gallbladder Neoplasms 12Bile Duct Neoplasms 11Melanoma 10Carcinoma 10Solid Tumors 9

Interventions

Brentuximab Vedotin 16ceritinib 3Rifampin 3brigatinib 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2Cyclophosphamide 2Crizotinib 210-propargyl-10-deazaaminopterin 2tislelizumab 1repotrectinib 1relatlimab 1ontuxizumab 1iratumumab 1entrectinib 1brincidofovir 1belinostat 1alectinib 1XMAB-2513 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Suspensions 1Nivolumab 1Midazolam 1MLN 8237 1Ketoconazole 1Itraconazole 1Folic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large-Cell, Anaplastic × Gemcitabine × Clear all
NCT00481871 2020-01-07

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Acrotech Biopharma Inc.

Phase 1/2 Completed
119 enrolled 13 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT00649584 2014-12-18

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Seagen Inc.

Phase 1 Terminated
44 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡